3 active not recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 3 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Unresectable Rectal Adenocarcinoma: new trials by email Literature Review of Unresectable Rectal Adenocarcinoma trials Research Report on Unresectable Rectal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Cetuximab, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2019-06-14 | 2026-06-11 |
Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Rectal Neoplasms (3) · Disease Progression (1)
Colonic Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Rectal Diseases (3) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Cetuximab (2) · Nivolumab (2) · LY3214996 (1) · abemaciclib (1) · encorafenib (1)
M.D. Anderson Cancer Center (3)
United States (3)
Alisha Bent, MD (1) · Christine M Parseghian, MD (1) · Van K Morris (1)
R01CA187238 (1)